{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:00:32Z","timestamp":1794369632696,"version":"4.9.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myasthenia gravis (MG) is characterized by muscle weakness caused by autoantibodies that bind to the postsynaptic membrane at the neuromuscular junction and impair acetylcholine receptor function. Weakness of respiratory muscles represents the most severe MG manifestation, and 10\u201315% of all patients experience an MG crisis with the need of mechanical ventilatory support at least once in their life. MG patients with respiratory muscle weakness need active immunosuppressive drug treatment long term, and they need regular specialist follow-up. Comorbidities affecting respiratory function need attention and optimal treatment. Respiratory tract infections can lead to MG exacerbations and precipitate an MG crisis. Intravenous immunoglobulin and plasma exchange are the core treatments for severe MG exacerbations. High-dose corticosteroids, complement inhibitors, and FcRn blockers represent fast-acting treatments that are effective in most MG patients. Neonatal myasthenia is a transient condition with muscle weakness in the newborn caused by mother\u2019s muscle antibodies. In rare cases, treatment of respiratory muscle weakness in the baby is required.<\/jats:p>","DOI":"10.1007\/s00415-023-11733-y","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T12:02:20Z","timestamp":1682510540000},"page":"3329-3340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Myasthenia gravis, respiratory function, and respiratory tract disease"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-5102","authenticated-orcid":false,"given":"Nils Erik","family":"Gilhus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"11733_CR1","first-page":"2","volume":"52","author":"SM Alises","year":"2018","unstructured":"Alises SM, Castano A, Voth AH, Pizarro N, Caneiras C, Diaz-Lobato S (2018) Efficacy of mechanical insufflation-exhalation therapy in patiens with neuromuscular disease. Eur Respir J 52:2","journal-title":"Eur Respir J"},{"key":"11733_CR2","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72:1548\u20131554","journal-title":"Neurology"},{"key":"11733_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/PHM.0000000000000538","volume":"96","author":"V Ambrogi","year":"2017","unstructured":"Ambrogi V, Mineo TC (2017) Benefits of comprehensive rehabilitation therapy in thymectomy for myasthenia gravis a propensity score matching analysis. Am J Phys Med Rehabil 96:77\u201383","journal-title":"Am J Phys Med Rehabil"},{"key":"11733_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/ane.12233","volume":"129","author":"JB Andersen","year":"2014","unstructured":"Andersen JB, Heldal AT, Engeland A, Gilhus NE (2014) Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand 129:26\u201331","journal-title":"Acta Neurol Scand"},{"key":"11733_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/ene.12439","volume":"21","author":"JB Andersen","year":"2014","unstructured":"Andersen JB, Owe JF, Engeland A, Gilhus NE (2014) Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. Eur J Neurol 21:948\u2013955","journal-title":"Eur J Neurol"},{"key":"11733_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/0885066620967646","volume":"37","author":"K Angstwurm","year":"2022","unstructured":"Angstwurm K, Vidal A, Stetefeld H, Dohmen C, Mergenthaler P, Kohler S, Schonenberger S, Bosel J, Neumann U, Lee DH, Gerner ST, Huttner HB, Thieme A, Dunkel J, Roth C, Schneider H, Schimmel E, Reichmann H, Fuhrer H, Berger B, Kleiter I, Schneider-Gold C, Alberty A, Zinke J, Schalke B, Steinbrecher A, Meisel A, Neumann B (2022) Early tracheostomy is associated with shorter ventilation time and duration of ICU stay in patients with myasthenic crisis\u2013a multicenter analysis. J Intensive Care Med 37:32\u201340","journal-title":"J Intensive Care Med"},{"key":"11733_CR7","doi-asserted-by":"crossref","unstructured":"Bach JF (2012) The etiology of autoimmune diseases: the case of myasthenia gravis. In: Wolfe GI, Meriggioli MN, Ciafaloni E, Ruff RL (eds) Myasthenia gravis and related disorders I. pp 33\u201339","DOI":"10.1111\/j.1749-6632.2012.06774.x"},{"key":"11733_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/1753495X211041899","volume":"15","author":"H Banner","year":"2022","unstructured":"Banner H, Niles KM, Ryu M, Sermer M, Bril V, Murphy KE (2022) Myasthenia gravis in pregnancy: systematic review and case series. Obstetr Med 15:108\u2013117","journal-title":"Obstetr Med"},{"key":"11733_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","volume":"87","author":"C Barnett","year":"2016","unstructured":"Barnett C, Bril V, Kapral M, Kulkarni A, Davis AM (2016) Development and validation of the Myasthenia Gravis Impairment Index. Neurology 87:879\u2013886","journal-title":"Neurology"},{"key":"11733_CR10","doi-asserted-by":"crossref","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW (1998) Reliability testing of the quantitative myasthenia gravis score. In: Richman DP (ed) Myasthenia gravis and related diseases: disorders of the neuromuscular junction. pp 769\u2013772","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"11733_CR11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1542\/peds.94.5.682","volume":"94","author":"DW Bianchi","year":"1994","unstructured":"Bianchi DW, Vanmarter LJ (1994) An approach to ventilator-dependent neonates with arthrogryposis. Pediatrics 94:682\u2013686","journal-title":"Pediatrics"},{"key":"11733_CR12","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","volume":"22","author":"S Blum","year":"2015","unstructured":"Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P (2015) Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci 22:1164\u20131169","journal-title":"J Clin Neurosci"},{"key":"11733_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12955-015-0298-1","volume":"13","author":"MI Boldingh","year":"2015","unstructured":"Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, Verschuuren J, Tallaksen CME (2015) An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes 13:2","journal-title":"Health Qual Life Outcomes"},{"key":"11733_CR14","unstructured":"Breiner A, Bourque PR. Vaccination against COVID-19 does not lead to exacerbation in patients with myasthenia gravis. Muscle Nerve"},{"key":"11733_CR15","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/mus.21185","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB, Grp MS (2008) Construction of an efficient evaluative instrument for myasthenia gravis: the mg composite. Muscle Nerve 38:1553\u20131562","journal-title":"Muscle Nerve"},{"key":"11733_CR16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M, Farrugia ME, Carmichael C, Birnbaum S, Hogrel JY, Nafissi S, Fatehi F, Ou CY, Liu WB, Conaway M (2016) International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15R. Muscle Nerve 54:1015\u20131022","journal-title":"Muscle Nerve"},{"key":"11733_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/mus.27324","volume":"64","author":"P Businaro","year":"2021","unstructured":"Businaro P, Vaghi G, Marchioni E, Diamanti L, Arceri S, Bini P, Colombo E, Cosentino G, Alfonsi E, Costa A, Ravaglia S, Mallucci G, Ballante E, Franciotta D, Gastaldi M (2021) COVID-19 in patients with myasthenia gravis: epidemiology and disease course. Muscle Nerve 64:206\u2013211","journal-title":"Muscle Nerve"},{"key":"11733_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.17712\/nsj.2019.2.20180024","volume":"24","author":"E Calik-Kutukcu","year":"2019","unstructured":"Calik-Kutukcu E, Salci Y, Karanfil E, Fil-Balkan A, Bekircan-Kurt CE, Armutlu K (2019) Expiratory muscle strength as a predictor of functional exercise capacity in generalized myasthenia gravis. Neurosciences 24:95\u2013100","journal-title":"Neurosciences"},{"key":"11733_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.imbio.2015.12.007","volume":"221","author":"P Cavalcante","year":"2016","unstructured":"Cavalcante P, Galbardi B, Franzi S, Marcuzzo S, Barzago C, Bonanno S, Camera G, Maggi L, Kapetis D, Andreetta F, Biasiucci A, Motta T, Giardina C, Antozzi C, Baggi F, Mantegazza R, Bernasconi P (2016) Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection. Immunobiology 221:516\u2013527","journal-title":"Immunobiology"},{"key":"11733_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnmol.2020.581097","volume":"13","author":"H Cetin","year":"2020","unstructured":"Cetin H, Beeson D, Vincent A, Webster R (2020) The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle. Front Mol Neurosci 13:25","journal-title":"Front Mol Neurosci"},{"key":"11733_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/jcm10174031","volume":"10","author":"CC Chang","year":"2021","unstructured":"Chang CC, Chen YK, Chiu HC, Yeh JH (2021) Changes in physical fitness and body composition associated with physical exercise in patients with myasthenia gravis: a longitudinal prospective study. J Clin Med 10:2","journal-title":"J Clin Med"},{"key":"11733_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/brb3.2242","volume":"11","author":"W Cheng","year":"2021","unstructured":"Cheng W, Sun T, Liu C, Zhou ZJ, Duan JX, Zhao YY, Yang M, Chen P (2021) A systematic review of myasthenia gravis complicated with myocarditis. Brain Behav 11:2","journal-title":"Brain Behav"},{"key":"11733_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1055\/s-2005-867071","volume":"25","author":"A Culebras","year":"2005","unstructured":"Culebras A (2005) Sleep disorders and neuromuscular disease. Semin Neurol 25:33\u201338","journal-title":"Semin Neurol"},{"key":"11733_CR24","unstructured":"De Leon AM, Aban I, McPherson T, Granit V, Benatar M, Cutter G, Lee IK Impact of the COVID-19 pandemic on patients with myasthenia gravis: a survey of the myasthenia gravis Foundation of America MG patient registry. Muscle Nerve"},{"key":"11733_CR25","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2019.07.006","volume":"29","author":"RHP de Meel","year":"2019","unstructured":"de Meel RHP, Tannemaat MR, Verschuuren J (2019) Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis. Neuromuscul Disord 29:664\u2013670","journal-title":"Neuromuscul Disord"},{"key":"11733_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-0404.2010.01369.x","volume":"122","author":"A Elsais","year":"2010","unstructured":"Elsais A, Johansen B, Kerty E (2010) Airway limitation and exercise intolerance in well-regulated myasthenia gravis patients. Acta Neurol Scand 122:12\u201317","journal-title":"Acta Neurol Scand"},{"key":"11733_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","volume":"1412","author":"A Evoli","year":"2018","unstructured":"Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, Marino M (2018) Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci 1412:82\u201389","journal-title":"Ann N Y Acad Sci"},{"key":"11733_CR28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","volume":"12","author":"A Evoli","year":"2013","unstructured":"Evoli A, Padua L (2013) Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 12:931\u2013935","journal-title":"Autoimmun Rev"},{"key":"11733_CR29","unstructured":"Farina A, Falso S, Cornacchini S, Spagni G, Monte G, Mariottini A, Massacesi L, Barilaro A, Evoli A, Damato V. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: a multicenter experience. Eur J Neurol"},{"key":"11733_CR30","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1378\/chest.128.3.1524","volume":"128","author":"GAD Fregonezi","year":"2005","unstructured":"Fregonezi GAD, Resqueti VR, Guell R, Pradas J, Casan P (2005) Effects of 8-week, interval-based inspiratory muscle training and breathing retraining in patients with generalized myasthenia gravis. Chest 128:1524\u20131530","journal-title":"Chest"},{"key":"11733_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.rmed.2018.09.001","volume":"144","author":"S Freitag","year":"2018","unstructured":"Freitag S, Hallebach S, Baumann I, Kalischewski P, Rassler B (2018) Effects of long-term respiratory muscle endurance training on respiratory and functional outcomes in patients with Myasthenia gravis. Respir Med 144:7\u201315","journal-title":"Respir Med"},{"key":"11733_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1055\/s-0036-1595816","volume":"64","author":"H Gaissert","year":"2016","unstructured":"Gaissert H, Wilcox SR (2016) Diaphragmatic dysfunction after thoracic operations. Thorac Cardiovasc Surg 64:621\u2013630","journal-title":"Thorac Cardiovasc Surg"},{"key":"11733_CR33","first-page":"2","volume":"2","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV (2012) Intravenous immunoglobulin for myasthenia gravis. Cochran Database Syst Rev 2:2","journal-title":"Cochran Database Syst Rev"},{"key":"11733_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.nmd.2020.12.004","volume":"31","author":"N Gilhus","year":"2021","unstructured":"Gilhus N (2021) Physical training and exercise in myasthenia gravis. Neuromuscul Disord 31:169\u2013173","journal-title":"Neuromuscul Disord"},{"key":"11733_CR35","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581","journal-title":"N Engl J Med"},{"key":"11733_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fneur.2020.00554","volume":"11","author":"NE Gilhus","year":"2020","unstructured":"Gilhus NE (2020) Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol 11:2","journal-title":"Front Neurol"},{"key":"11733_CR37","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/ene.13788","volume":"25","author":"NE Gilhus","year":"2018","unstructured":"Gilhus NE, Hong Y (2018) Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol 25:1402\u20131409","journal-title":"Eur J Neurol"},{"key":"11733_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ene.12599","volume":"22","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Nacu A, Andersen JB, Owe JF (2015) Myasthenia gravis and risks for comorbidity. Eur J Neurol 22:17\u201323","journal-title":"Eur J Neurol"},{"key":"11733_CR39","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","volume":"265","author":"NE Gilhus","year":"2018","unstructured":"Gilhus NE, Romi F, Hong Y, Skeie GO (2018) Myasthenia gravis and infectious disease. J Neurol 265:1251\u20131258","journal-title":"J Neurol"},{"key":"11733_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia gravis. Nat Rev Dis Prim 5:30","journal-title":"Nat Rev Dis Prim"},{"key":"11733_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palaces J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Prim 5:30","journal-title":"Nat Rev Dis Prim"},{"key":"11733_CR42","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.nmd.2021.07.396","volume":"31","author":"NE Gilhus","year":"2021","unstructured":"Gilhus NE, Verschuuren J, Hovland SIB, Simmonds H, Groot F, Palace J (2021) Myasthenia gravis: do not forget the patient perspective. Neuromuscul Disord 31:1287\u20131295","journal-title":"Neuromuscul Disord"},{"key":"11733_CR43","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"key":"11733_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141\u2013149","journal-title":"Muscle Nerve"},{"key":"11733_CR45","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00415-015-7638-2","volume":"262","author":"MC Gui","year":"2015","unstructured":"Gui MC, Luo X, Lin J, Li Y, Zhang M, Zhang XF, Yang MS, Wang W, Bu BT (2015) Long-term outcome of 424 childhood-onset myasthenia gravis patients. J Neurol 262:823\u2013830","journal-title":"J Neurol"},{"key":"11733_CR46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jcrc.2016.03.006","volume":"34","author":"K Haji","year":"2016","unstructured":"Haji K, Royse A, Green C, Botha J, Canty D, Royse C (2016) Interpreting diaphragmatic movement with bedside imaging, review article. J Crit Care 34:56\u201365","journal-title":"J Crit Care"},{"key":"11733_CR47","unstructured":"Hamedani AG, Thibault D, Willis AW. Seasonal Variation in Neurologic Hospitalizations in the United States. Ann Neurol"},{"key":"11733_CR48","unstructured":"Hannan LM, De Losa R, Romeo N, Muruganandan S. Diaphragm dysfunction: a comprehensive review from diagnosis to management. Intern Med J"},{"key":"11733_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/mus.24697","volume":"53","author":"JS Hansen","year":"2016","unstructured":"Hansen JS, Danielsen DH, Somnier FE, Froslev T, Jakobsen J, Johnsen SP, Andersen H (2016) mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark. Muscle Nerve 53:73\u201377","journal-title":"Muscle Nerve"},{"key":"11733_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12883-022-02692-4","volume":"22","author":"L Harris","year":"2022","unstructured":"Harris L, Graham S, MacLachlan S, Exuzides A, Jacob S (2022) A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. Bmc Neurol 22:43","journal-title":"Bmc Neurol"},{"key":"11733_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10072-019-3706-1","volume":"40","author":"SJ Heo","year":"2019","unstructured":"Heo SJ, Jun JS, Park D, Lee HW, Kim JS, Park JS (2019) Characteristics of obstructive sleep apnea in myasthenia gravis patients: a single center study. Neurol Sci 40:719\u2013724","journal-title":"Neurol Sci"},{"key":"11733_CR52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejogrb.2011.09.027","volume":"159","author":"JM Hoff","year":"2011","unstructured":"Hoff JM, Loane M, Gilhus NE, Rasmussen S, Daltveit AK (2011) Arthrogryposis multiplexa congenita: an epidemiologic study of nearly 9 million births in 24 EUROCAT registers. Eur J Obstetr Gynecol Reprod Biol 159:347\u2013350","journal-title":"Eur J Obstetr Gynecol Reprod Biol"},{"key":"11733_CR53","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.humimm.2011.12.022","volume":"73","author":"A Holbro","year":"2012","unstructured":"Holbro A, Jauch A, Lardinois D, Tzankov A, Dirnhofer S, Hess C (2012) High prevalence of infections and autoimmunity in patients with thymoma. Hum Immunol 73:287\u2013290","journal-title":"Hum Immunol"},{"key":"11733_CR54","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1002\/mus.26859","volume":"62","author":"J Howard","year":"2020","unstructured":"Howard J, Vu T, Bril V, De Bleecker J, Verschuuren J, Mantegazza R, Meisel A, Peric S, de Haard H, Parys W, Guglietta A, Ulrichts P, Murai H (2020) ADAPT: a phase 3 study of fcrn antagonist, efgartigimod, in myasthenia gravis. Muscle Nerve 62:S76\u2013S76","journal-title":"Muscle Nerve"},{"key":"11733_CR55","first-page":"4","volume":"3","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, al e, (2017) REGAIN: a randomised, double-blind, placebo-controlled, multi-centre study to evaluate the safety and efficacy of eculizumab in patients with anti-acetylcholine receptor positive refractory generalised myasthenia gravis. Lancet Neurol 3:4","journal-title":"Lancet Neurol"},{"key":"11733_CR56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1155\/2020\/2923907","volume":"2020","author":"CW Hsu","year":"2020","unstructured":"Hsu CW, Lin HC, Tsai WC, Lai YR, Huang CC, Su YJ, Cheng BC, Su MC, Lin WC, Chang CL, Chang WN, Lin MC, Lu CH, Tsai NW (2020) Respiratory muscle training improves functional outcomes and reduces fatigue in patients with myasthenia gravis: a single-center hospital-based prospective study. Biomed Res Int 2020:2","journal-title":"Biomed Res Int"},{"key":"11733_CR57","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10072-012-1157-z","volume":"34","author":"X Huang","year":"2013","unstructured":"Huang X, Liu WB, Men LN, Feng HY, Li Y, Luo CM, Qiu L (2013) Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci 34:911\u2013917","journal-title":"Neurol Sci"},{"key":"11733_CR58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000506189","volume":"12","author":"K Inoue","year":"2020","unstructured":"Inoue K, Tsugawa J, Fukae J, Fukuhara K, Kawano H, Fujioka S, Tsuboi Y (2020) Myasthenia gravis with anti-muscle-specific tyrosine kinase antibody during pregnancy and risk of neonatal myasthenia gravis: a case report and review of the literature. Case Rep Neurol 12:114\u2013120","journal-title":"Case Rep Neurol"},{"key":"11733_CR59","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/01616412.2017.1407021","volume":"40","author":"K Iwasa","year":"2018","unstructured":"Iwasa K, Yoshikawa H, Hamaguchi T, Sakai K, Shinohara-Noguchi M, Samuraki M, Takahashi K, Yanase D, Ono K, Ishida C, Yoshita M, Nakamura H, Yamada M (2018) Time-series analysis: variation of anti-acetylcholine receptor antibody titer in myasthenia gravis is related to incidence of Mycoplasma pneumoniae and influenza virus infections. Neurol Res 40:102\u2013109","journal-title":"Neurol Res"},{"key":"11733_CR60","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1111\/ene.14951","volume":"28","author":"M Jakubikova","year":"2021","unstructured":"Jakubikova M, Tyblova M, Tesar A, Horakova M, Vlazna D, Rysankova I, Novakova I, Doleckova K, Dusek P, Pitha J, Vohanka S, Bednarik J (2021) Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol 28:3418\u20133425","journal-title":"Eur J Neurol"},{"key":"11733_CR61","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/ene.14153","volume":"27","author":"CD Kassardjian","year":"2020","unstructured":"Kassardjian CD, Widdifield J, Paterson JM, Kopp A, Nagamuthu C, Barnett C, Tu K, Breiner A (2020) Serious infections in patients with myasthenia gravis: population-based cohort study. Eur J Neurol 27:702\u2013708","journal-title":"Eur J Neurol"},{"key":"11733_CR62","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/0883073820924213","volume":"35","author":"HD Katzberg","year":"2020","unstructured":"Katzberg HD, Vajsar J, Vezina K, Qashqari H, Selvadurai S, Chrestian N, Khayat A, Ryan CM, Narang I (2020) Respiratory dysfunction and sleep-disordered breathing in children with myasthenia gravis. J Child Neurol 35:600\u2013606","journal-title":"J Child Neurol"},{"key":"11733_CR63","first-page":"54","volume":"13","author":"Y Kim","year":"2022","unstructured":"Kim Y, Li XJ, Huang Y, Kim M, Shaibani A, Sheikh K, Zhang GQ, Nguyen TP (2022) COVID-19 outcomes in myasthenia gravis patients: analysis from electronic health records in the United States. Front Neurol 13:54","journal-title":"Front Neurol"},{"key":"11733_CR64","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1038\/s41372-021-00970-6","volume":"41","author":"PK Kochhar","year":"2021","unstructured":"Kochhar PK, Schumacher RE, Sarkar S (2021) Transient neonatal myasthenia gravis: refining risk estimate for infants born to women with myasthenia gravis. J Perinatol 41:2279\u20132283","journal-title":"J Perinatol"},{"key":"11733_CR65","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","volume":"268","author":"N Konig","year":"2021","unstructured":"Konig N, Stetefeld HR, Dohmen C, Mergenthaler P, Kohler S, Schonenberger S, Bosel J, Lee DH, Gerner ST, Huttner HB, Schneider H, Reichmann H, Fuhrer H, Berger B, Zinke J, Alberty A, Kleiter I, Schneider-Gold C, Roth C, Dunkel J, Steinbrecher A, Thieme A, Schlachetzki F, Linker RA, Angstwurm K, Meisel A, Neumann B (2021) MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation. J Neurol 268:4824\u20134833","journal-title":"J Neurol"},{"key":"11733_CR66","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/mus.26987","volume":"62","author":"K Kukulka","year":"2020","unstructured":"Kukulka K, Gummi RR, Govindarajan R (2020) A telephonic single breath count test for screening of exacerbations of myasthenia gravis: a pilot study. Muscle Nerve 62:258\u2013261","journal-title":"Muscle Nerve"},{"key":"11733_CR67","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.anl.2018.10.004","volume":"46","author":"Y Kumai","year":"2019","unstructured":"Kumai Y, Miyamoto T, Matsubara K, Samejima Y, Yamashita S, Ando Y, Orita Y (2019) Assessment of oropharyngeal swallowing dysfunction in myasthenia gravis patients presenting with difficulty in swallowing. Auris Nasus Larynx 46:390\u2013396","journal-title":"Auris Nasus Larynx"},{"key":"11733_CR68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12890-021-01391-z","volume":"21","author":"FA Laghi","year":"2021","unstructured":"Laghi FA, Saad M, Shaikh H (2021) Ultrasound and non-ultrasound imaging techniques in the assessment of diaphragmatic dysfunction. Bmc Pulmon Med 21:32","journal-title":"Bmc Pulmon Med"},{"key":"11733_CR69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/mus.23869","volume":"49","author":"AA Leis","year":"2014","unstructured":"Leis AA, Szatmary G, Ross MA, Stokic DS (2014) West nile virus infection and myasthenia gravis. Muscle Nerve 49:26\u201329","journal-title":"Muscle Nerve"},{"key":"11733_CR70","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/13548506.2020.1807577","volume":"26","author":"CC Liu","year":"2021","unstructured":"Liu CC, Li T, Wang QY, Xu AD, Wu BQ (2021) Post-traumatic stress disorder symptoms after respiratory insufficiency in patients with myasthenia gravis. Psychol Health Med 26:221\u2013227","journal-title":"Psychol Health Med"},{"key":"11733_CR71","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/j.1468-1331.2011.03621.x","volume":"19","author":"CJ Liu","year":"2012","unstructured":"Liu CJ, Chang YS, Teng CJ, Chen TJ, Ou SM, Tzeng CH, Wang SJ (2012) Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. Eur J Neurol 19:746\u2013751","journal-title":"Eur J Neurol"},{"key":"11733_CR72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12883-019-1384-5","volume":"19","author":"F Liu","year":"2019","unstructured":"Liu F, Wang Q, Chen XP (2019) Myasthenic crisis treated in a Chinese neurological intensive care unit: clinical features, mortality, outcomes, and predictors of survival. Bmc Neurol 19:22","journal-title":"Bmc Neurol"},{"key":"11733_CR73","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/neurolint14020033","volume":"14","author":"A Lupica","year":"2022","unstructured":"Lupica A, Di Stefano V, Iacono S, Pignolo A, Quartana M, Gagliardo A, Fierro B, Brighina F (2022) Impact of COVID-19 in AChR myasthenia gravis and the safety of vaccines: data from an Italian cohort. Neurol Int 14:406\u2013416","journal-title":"Neurol Int"},{"key":"11733_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1\u201311","journal-title":"Ther Adv Neurol Disord"},{"key":"11733_CR75","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2105-15-S6-S3","volume":"15","author":"RD Melamed","year":"2014","unstructured":"Melamed RD, Khiabanian H, Rabadan R (2014) Data-driven discovery of seasonally linked diseases from an electronic health records system. Bmc Bioinform 15:22","journal-title":"Bmc Bioinform"},{"key":"11733_CR76","doi-asserted-by":"publisher","first-page":"648","DOI":"10.4103\/0028-3886.289001","volume":"68","author":"UK Misra","year":"2020","unstructured":"Misra UK, Kumar S, Singh VK, Dubey D, Kalita J (2020) Noninvasive ventilation in myasthenia gravis. Neurol India 68:648\u2013651","journal-title":"Neurol India"},{"key":"11733_CR77","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","volume":"48","author":"A Nacu","year":"2015","unstructured":"Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE (2015) Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity 48:362\u2013368","journal-title":"Autoimmunity"},{"key":"11733_CR78","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N, Mergenthaler P, Arat E, Ozturk M, Foell D, Schreiber S, Vielhaber S, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Wiendl H, Ruck T (2022) Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflam 19:2","journal-title":"J Neuroinflam"},{"key":"11733_CR79","doi-asserted-by":"publisher","first-page":"E299","DOI":"10.1212\/WNL.0000000000008688","volume":"94","author":"B Neumann","year":"2020","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Schonenberger S, Bosel J, Neumann U, Vidal A, Huttner HB, Gerner ST, Thieme A, Steinbrecher A, Dunkel J, Roth C, Schneider H, Schimmel E, Fuhrer H, Fahrendorf C, Alberty A, Zinke J, Meisel A, Dohmen C, Stetefeld HR (2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94:E299\u2013E313","journal-title":"Neurology"},{"key":"11733_CR80","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/mus.24556","volume":"52","author":"S Ohlraun","year":"2015","unstructured":"Ohlraun S, Hoffmann S, Klehmet J, Kohler S, Grittner U, Schneider A, Heuschmann PU, Meisel A (2015) Impact of myasthenia gravis on family planning: how do women with myasthenia gravis decide and why? Muscle Nerve 52:371\u2013379","journal-title":"Muscle Nerve"},{"key":"11733_CR81","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/jnnp.2005.072355","volume":"77","author":"JF Owe","year":"2006","unstructured":"Owe JF, Daltveit AK, Gilhus NE (2006) Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiatry 77:203\u2013207","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11733_CR82","doi-asserted-by":"publisher","unstructured":"Patone M, Handunnetthi L, Saatci D, Pan JF, Katikireddi SV, Razvi S, Hunt D, Mei XW, Dixon S, Zaccardi F, Khunti K, Watkinson P, Coupland CAC, Doidge J, Harrison DA, Ravanan R, Sheikh A, Robertson C, Hippisley-Cox J (2021) Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection (Oct, https:\/\/doi.org\/10.1038\/s41591-021-01556-7, 2021). Nat Med 27:2249\u20132249","DOI":"10.1038\/s41591-021-01556-7"},{"key":"11733_CR83","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fimmu.2022.1103020","volume":"13","author":"SY Peng","year":"2022","unstructured":"Peng SY, Tian YK, Meng LH, Fang RY, Chang WQ, Yang YJ, Li SH, Shen QQ, Ni JX, Zhu WZ (2022) The safety of COVID-19 vaccines in patients with myasthenia gravis: a scoping review. Front Immunol 13:2","journal-title":"Front Immunol"},{"key":"11733_CR84","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mus.27657","volume":"66","author":"AU Pincheira","year":"2022","unstructured":"Pincheira AU, Alnajjar S, Katzberg H, Barnett C, Daniyal L, Rohan R, Bril V (2022) Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis. Muscle Nerve 66:558\u2013561","journal-title":"Muscle Nerve"},{"key":"11733_CR85","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-021-02090-y","volume":"16","author":"LI Pisella","year":"2021","unstructured":"Pisella LI, Fernandes S, Sole G, Stojkovic T, Tard C, Chanson JB, Bouhour F, Salort-Campana E, Beaudonnet G, Deberge L, Duval F, Grapperon AM, Masingue M, Nadaj-Pakleza A, Pereon Y, Audic F, Behin A, Friedman D, Magot A, Noury JB, Souvannanorath S, Wahbi K, Antoine JC, Bigaut K, Camdessanche JP, Cintas P, Debs R, Espil-Taris C, Kremer L, Kuntzer T, Laforet P, Laugel V, Mallaret M, Michaud M, Nollet S, Svahn J, Vicart S, Villar-Quiles RN, Desguerre I, Adams D, Segovia-Kueny S, Merret G, Hammouda E, Molon A, Attarian S (2021) A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases. Orphanet J Rare Dis 16:2","journal-title":"Orphanet J Rare Dis"},{"key":"11733_CR86","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ejpn.2017.04.003","volume":"21","author":"TH Popperud","year":"2017","unstructured":"Popperud TH, Boldingh MI, Rasmussen M, Kerty E (2017) Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. Eur J Paediatr Neurol 21:707\u2013714","journal-title":"Eur J Paediatr Neurol"},{"key":"11733_CR87","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jcv.2013.08.035","volume":"58","author":"M Prelog","year":"2013","unstructured":"Prelog M, Egli A, Zlamy M, Hirsch HH (2013) JC and BK polyomavirus-specific immunoglobulin G responses in patients thymectomized in early childhood. J Clin Virol 58:553\u2013558","journal-title":"J Clin Virol"},{"key":"11733_CR88","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/ene.12703","volume":"22","author":"A Ramos-Fransi","year":"2015","unstructured":"Ramos-Fransi A, Rojas-Garcia R, Segovia S, Marquez-Infante C, Pardo J, Coll-Canti J, Jerico I, Illa I, Myasthenia NMDESSG (2015) Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol 22:1056\u20131061","journal-title":"Eur J Neurol"},{"key":"11733_CR89","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nmd.2007.01.001","volume":"17","author":"B Rassler","year":"2007","unstructured":"Rassler B, Hallebach G, Kalischewski P, Baumann I, Schauer J, Spengler CM (2007) The effect of respiratory muscle endurance training in patients with myasthenia gravis. Neuromuscul Disord 17:385\u2013391","journal-title":"Neuromuscul Disord"},{"key":"11733_CR90","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fneur.2020.00660","volume":"11","author":"C Rodolico","year":"2020","unstructured":"Rodolico C, Bonanno C, Toscano A, Vita G (2020) MuSK-associated myasthenia gravis: clinical features and management. Front Neurol 11:2","journal-title":"Front Neurol"},{"key":"11733_CR91","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archneur.62.3.442","volume":"62","author":"F Romi","year":"2005","unstructured":"Romi F, Skeie GO, Gilhus NE, Aarli JA (2005) Striational antibodies in myasthenia gravis\u2014reactivity and possible clinical significance. Arch Neurol 62:442\u2013446","journal-title":"Arch Neurol"},{"key":"11733_CR92","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","volume":"14","author":"F Romi","year":"2007","unstructured":"Romi F, Aarli JA, Gilhus NE (2007) Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 14:617\u2013620","journal-title":"Eur J Neurol"},{"key":"11733_CR93","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jemermed.2017.06.009","volume":"53","author":"J Roper","year":"2017","unstructured":"Roper J, Fleming ME, Long B, Koyfman A (2017) Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med 53:843\u2013853","journal-title":"J Emerg Med"},{"key":"11733_CR94","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","volume":"30","author":"AM Ruiter","year":"2020","unstructured":"Ruiter AM, Verschuuren J, Tannemaat MR (2020) Fatigue in patients with myasthenia gravis. A systematic review of the literature. Neuromuscul Disord 30:631\u2013639","journal-title":"Neuromuscul Disord"},{"key":"11733_CR95","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1007\/s00415-022-11140-9","volume":"269","author":"G Sansone","year":"2022","unstructured":"Sansone G, Bonifati DM (2022) Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients. J Neurol 269:3965\u20133981","journal-title":"J Neurol"},{"key":"11733_CR96","first-page":"2","volume":"14","author":"C Schneider-Gold","year":"2021","unstructured":"Schneider-Gold C, Gilhus NE (2021) Advances and challenges in the treatment of myasthenia gravis. Therap Adv Neurol Disord 14:2","journal-title":"Therap Adv Neurol Disord"},{"key":"11733_CR97","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3988\/jcn.2017.13.4.325","volume":"13","author":"HY Seok","year":"2017","unstructured":"Seok HY, Shin HY, Kim JK, Kim BJ, Oh J, Suh BC, Kim SY, Kang SY, Ahn SW, Bae JS, Kim BJ (2017) The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis. J Clin Neurol 13:325\u2013330","journal-title":"J Clin Neurol"},{"key":"11733_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-022-11389-0","volume":"270","author":"F Stascheit","year":"2023","unstructured":"Stascheit F, Grittner U, Hoffmann S, Mergenthaler P, Schroeter M, Ruck T, Pawlitzki M, Blaes F, Kaiser J, Schara U, Della-Marina A, Thieme A, Hagenacker T, Jacobi C, Berger B, Urban PP, Knop KC, Schalke B, Lee DH, Kalischewski P, Wiendl H, Meisel A (2023) Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis. J Neurol 270:1\u201312","journal-title":"J Neurol"},{"key":"11733_CR99","first-page":"301","volume":"86","author":"HR Stetefeld","year":"2018","unstructured":"Stetefeld HR, Schroeter M (2018) Myasthenic crisis. fortschritte der neurologie. Psychiatrie 86:301\u2013307","journal-title":"Psychiatrie"},{"key":"11733_CR100","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","volume":"37","author":"E Strijbos","year":"2019","unstructured":"Strijbos E, Tannemaat MR, Alleman I, de Meel RHP, Bakker JA, van Beek R, Kroon FP, Rimmelzwaan GF, Verschuuren J (2019) A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine 37:919\u2013925","journal-title":"Vaccine"},{"key":"11733_CR101","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ene.12234","volume":"21","author":"S Suzuki","year":"2014","unstructured":"Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, Ogawa G, Nagane Y, Kuwana M, Suzuki N (2014) Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol 21:223\u2013230","journal-title":"Eur J Neurol"},{"key":"11733_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596382","volume":"11","author":"JLS Thomsen","year":"2020","unstructured":"Thomsen JLS, Andersen H (2020) Outcome measures in clinical trials of patients with myasthenia gravis. Front Neurol 11:596382","journal-title":"Front Neurol"},{"key":"11733_CR103","doi-asserted-by":"publisher","first-page":"E1426","DOI":"10.1212\/WNL.0000000000010209","volume":"95","author":"M Tomschik","year":"2020","unstructured":"Tomschik M, Hilger E, Rath J, Mayer EM, Fahrner M, Cetin H, Loscher WN, Zimprich F (2020) Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology 95:E1426\u2013E1436","journal-title":"Neurology"},{"key":"11733_CR104","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.nmd.2018.04.001","volume":"28","author":"M Turk","year":"2018","unstructured":"Turk M, Weber I, Vogt-Ladner G, Schroder R, Winterholler M (2018) Diaphragmatic dysfunction as the presenting symptom in neuromuscular disorders: a retrospective longitudinal study of etiology and outcome in 30 German patients. Neuromuscul Disord 28:484\u2013490","journal-title":"Neuromuscul Disord"},{"key":"11733_CR105","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","volume":"19","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R (2022) Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics 19:897\u2013910","journal-title":"Neurotherapeutics"},{"key":"11733_CR106","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/pn-2022-003422","volume":"22","author":"J Walters","year":"2022","unstructured":"Walters J (2022) Weakness in the intensive care unit. Pract Neurol 22:358","journal-title":"Pract Neurol"},{"key":"11733_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109058","volume":"241","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huan X, Jiao KX, Jiang QL, Goh LY, Shi JQ, Lv ZG, Xi JY, Song J, Yan C, Lin J, Zhu WH, Zhu XF, Zhou ZR, Xia R, Luo SS, Zhao CB (2022) Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study. Clin Immunol 241:109058","journal-title":"Clin Immunol"},{"key":"11733_CR108","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011510","volume":"97","author":"E Westerberg","year":"2018","unstructured":"Westerberg E, Molin CJ, Nees S, Widenfalk J, Punga AR (2018) The impact of physical exercise on neuromuscular function in Myasthenia gravis patients A single-subject design study. Medicine 97:e11510","journal-title":"Medicine"},{"key":"11733_CR109","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.nmd.2020.08.355","volume":"30","author":"E Westerberg","year":"2020","unstructured":"Westerberg E, Punga AR (2020) Mortality rates and causes of death in Swedish Myasthenia Gravis patients. Neuromuscul Disord 30:815\u2013824","journal-title":"Neuromuscul Disord"},{"key":"11733_CR110","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"Wolfe G, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ","year":"1999","unstructured":"Wolfe G, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487\u20131489","journal-title":"Neurology"},{"key":"11733_CR111","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.amjoto.2018.11.002","volume":"40","author":"XL Yang","year":"2019","unstructured":"Yang XL, Niu L, Yang CW, Wang L, Liu JX, He GY (2019) Clinical features of laryngeal myasthenia gravis: a case series. Am J Otolaryngol 40:292\u2013296","journal-title":"Am J Otolaryngol"},{"key":"11733_CR112","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00408-021-00444-8","volume":"199","author":"P Yingchoncharoen","year":"2021","unstructured":"Yingchoncharoen P, Charoenngam N, Ponvilawan B, Thongpiya J, Chaikijurajai T, Ungprasert P (2021) The association between asthma and risk of myasthenia gravis: a systematic review and meta-analysis. Lung 199:273\u2013280","journal-title":"Lung"},{"key":"11733_CR113","first-page":"2","volume":"13","author":"YF Zhou","year":"2022","unstructured":"Zhou YF, Chen JL, Li ZB, Tan S, Yan C, Luo SS, Zhou L, Song J, Huan X, Wang Y, Zhao CB, Zeng WS, Xi JY (2022) Clinical features of myasthenia gravis with antibodies to MuSK based on age at onset: a multicenter retrospective study in China. Front Neurol 13:2","journal-title":"Front Neurol"},{"key":"11733_CR114","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.autrev.2013.03.002","volume":"12","author":"P Zisimopoulou","year":"2013","unstructured":"Zisimopoulou P, Brenner T, Trakas N, Tzartos SJ (2013) Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 12:924\u2013930","journal-title":"Autoimmun Rev"},{"key":"11733_CR115","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Cuvelier MF, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139\u2013145","journal-title":"J Autoimmun"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11733-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11733-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T12:05:44Z","timestamp":1686744344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11733-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["11733"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11733-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"8 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.E. Gilhus has received financial support from UCB, Argenx, Janssen, Alexion, Merck, Roche, and Immunovant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}